<DOC>
	<DOCNO>NCT00755534</DOCNO>
	<brief_summary>This phase II study evaluate best way administer cetuximab recurrence 1st line irinotecan+bevacizumab base treatment obtain result efficacy oxaliplatin+cetuximab combination 2nd line treatment .</brief_summary>
	<brief_title>Irinotecan/Cetuximab Followed XELOX/Cetuximab v Reverse Sequence Metastatic CRC</brief_title>
	<detailed_description>Because recent advance field systemic chemotherapy mCRC , like irinotecan , oxaliplatin , capecitabine , target agent ( Cetuximab , Bevacizumab ) mCRC patient overall survival case reach 25 months.Irinotecan inhibitor DNA enzyme topoisomerase I , use clinical practice last 10 years.In phase II study mCRC patient resistant irinotecan base therapy combination irinotecan Cetuximab ( IgG1 anti-EGFR antibody ) yield response rate 22.5 % .Capecitabine show improved tolerability response rate compare bolus 5-FU , comparable time progression survival.Oxaliplatin approve FDA 2nd line treatment metastatic CRC set number trial show promise data response rate , disease stabilization rate , median progression free survival ( PFS ) overall survival ( OS ) .KRAS predictive marker clinical benefit EGFR-based antibody treatment . KRAS first molecular marker selection target therapy combination standard chemotherapy regimen . Patients KRAS wild-type tumor strong benefit administration cetuximab well PFS objective response .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Histologically confirm locally advanced metastatic colorectal cancer Measurable evaluable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) ECOG performance status ≤ 2 Age 18 72 year Patients CR , PR SD 1st line therapy base Irinotecan+Bevacizumab Paraffin block primary tumor order perform tha mutational analysis KRAS gene Adequate liver ( Bilirubin ≤ 1.5 upper normal limit , SGOT/SGPT ≤ 4 upper normal limit , ALP ≤ 2.5 upper normal limit ) , renal ( Creatinine ≤ 1.5 upper normal limit ) bone marrow ( ANC ≥ 1,500/mm3 , PLT ≥100,000/mm3 ) function Patients must able understand nature study Written inform consent Presence central nervous system brain metastasis Pregnant lactate woman Life expectancy &lt; 3 month Previous radiotherapy within last 4 week &gt; 25 % bone marrow field treatment target locate Peripheral neuropathy grade ≥2 Known hypersensitivity Erbitux Metastatic infiltration liver &gt; 50 % Patients chronic diarrhea ( least 3 month ) partial bowel obstruction total colectomy Active infection Second primary malignancy , except nonmelanoma skin cancer situ cervical cancer Psychiatric illness social situation would preclude study compliance</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>72 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Metastatic colorectal cancer</keyword>
	<keyword>Second line</keyword>
	<keyword>Irinotecan</keyword>
	<keyword>Cetuximab ( Erbitux )</keyword>
	<keyword>Capecitabine ( Xeloda )</keyword>
</DOC>